Racial disparities in cancer treatment and outcomes are common and well-documented. According to a new study published in JAMA Oncology, minority patients with cancer also experience disparities in the cultural competency of their physician, including access to physicians who understand their culture. The study evaluated patient data from 2244 adult cancer survivors participating in the […]

Effective clinical research requires a continuous stream of data, but gathering real-world data isn’t always easy. It can be particularly tricky for pharmaceutical manufacturer researchers to connect with practicing oncologists. Community oncologists have many demands on their time and may not be available to participate in clinical research when you need them most. However, their […]

Emerging Oncology Trends Dramatic advances within the last decade have reshaped the global oncology market. A record number of new cancer drugs have received regulatory approval. Some of these treatments, such as immunotherapies, have permanently altered the way we approach cancer treatment. Yet while the global oncology market has enjoyed many triumphs, the industry continues […]

Immunotherapies have become a standard treatment for many patients with cancer. While these agents can be highly effective and associated with durable responses and improved long-term survival, they are also associated with a unique and potentially serious adverse event profile. Appropriate management of immune-related adverse events (irAEs) is essential for successful treatment with immunotherapies. To […]

While hundreds of clinical trials in lung cancer are completed each year, results from many trials will not be publicly released or published in a peer-reviewed journal. According to a study published in JAMA Network Open, results from as many as 25% of lung cancer clinical trials are never published. Researchers evaluated phase II and […]